Page 15 - Anjali Singh

Lupin signs licensing deal with SteinCares for ranibizumab in LatAm

Lupin will manufacture biosimilar ranibizumab while SteinCares handles registration and marketing in Latin America, excluding Mexico and Argentina

Indian tyre companies draw up road map to steer through tariff jitters

Despite low US exposure, Indian tyre makers are crafting mitigation strategies to address looming tariff threats and persistent margin pressures due to high input costs

Private hospitals step up Covid readiness amid mild case uptick in India

Despite a mild rise in cases and no fresh central advisory, private hospitals across India are enhancing Covid protocols and issuing cautionary measures to safeguard high-risk groups

Private hospitals reinforce Covid-19 readiness amid mild case uptick

Hospitals across India reinstate early-pandemic protocols and bolster isolation facilities as active COVID cases rise, though most remain mild and manageable

Sun Pharma results: Profit down 19% at Rs 2,149.8 cr, revenue up 8%

Sun Pharma attributed the lower growth in the quarter partly to softer sales in January and February in the US, which is a typical trend

Tata Motors bets on Altroz to 2x market share in premium hatchbacks

The 25,000-30,000 units a month premium hatchback segment accounts for nearly 6-7 per cent of passenger vehicle (PV) sales, and is dominated by models like Baleno of Maruti Suzuki

Auto parts sector to grow 7-9% in FY26, driven by 2W, PV demand: Crisil

A moderate recovery in commercial vehicles and tractor sales, which contribute around 17 per cent to overall revenue, is also expected to support growth

Zydus reports 17.6% rise in net profit adjusting for one-off charge

Q4 revenue up 17%

JK Tyre Q4FY25 profit down 42.6% to Rs 97 crore, revenue up 1.63%

JK Tyre's net profit fell 42.6% in Q4FY25 due to raw material inflation; revenue rose modestly, with premium product lines showing strong customer traction

5 products to be launched in 18 mths, US insulin mkt share up: BBL MD & CEO

Achieving 15 per cent year-on-year growth, with nearly four biosimilars with $200 million in revenue, is a big feat, says Tambe

GS1 to roll out next-generation barcodes by 2027 to boost transparency

GS1 will replace traditional barcodes with advanced 2D formats by 2027 to enhance supply chain traceability, support recall tracking and integrate with smart technologies

Lumax Auto to acquire remaining 25% stake in IAC India for Rs 221 cr

LATL will acquire full control of IAC India by 31 May for Rs 221 crore, strengthening its position in EV interiors and aiming for post-merger synergies and growth

Fire disrupts production at GSK Pharma's contract manufacturing site

GSK Pharmaceuticals has reported a fire at one of its contract sites, causing temporary disruption; the company is assessing the impact and working to restore operations

Belrise eyes four-wheeler, CV push ahead of ₹2,150-cr IPO on May 21

Belrise Industries, dominant in two-wheeler components, plans to expand into CVs and four-wheelers as it raises ₹2,150 crore through an IPO opening on May 21

PV dealers likely to post 7-9% revenue growth in FY26: Crisil Ratings

Passenger vehicle dealerships may see margin recovery and stable credit profiles in FY26 as SUV demand, rural recovery, and higher-margin services bolster growth

Tata AutoComp, Katcon tie up in Mexico to make composites for NA market

The new Mexico-based venture will cater to North American OEMs with composite solutions aimed at improving vehicle efficiency and meeting weight-reduction targets

JB Pharma Q4 results: Profit up 15% to ₹145.6 cr; revenue rises 10%

JB Pharma posts strong FY25 performance with 19.3% profit growth; domestic business up 20%, CDMO segment and Russia drive international gains

Eicher Motors Q4 results: Profit up 27%; Royal Enfield sets sales record

Eicher Motors reported record Q4 and FY25 results, with 27% rise in profit, record Royal Enfield sales, and plans to launch its first electric bikes in FY26

Cipla Q4FY25 results: Net profit zooms 30% to ₹1,221 cr, revenue up 9%

Profit exceeded Bloomberg estimates by 19.4 per cent, whereas the revenue fell along the expected lens growing 0.28 per cent

Metropolis Healthcare Q4 results: Net profit falls 19.9%, revenue up 4.3%

Metropolis Q4 profit dips due to one-off costs from acquisitions; FY25 profit rises 13.4% on demand for preventive testing and strong B2C, B2B growth